Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis and cruris
Pakistan Journal of Pharmaceutical Sciences. 2017; 30 (3 [Special]): 1103-1106
in En
| IMEMR
| ID: emr-189318
Responsible library:
EMRO
ABSTRACT
The paper is intended to analyze and evaluate the specific curative effect and safety of 2% liranaftate ointment in treating patients with tinea pedis and tinea cruris. 1,100 cases of patients with tinea pedis and tinea corporis and cruris were selected as research objects and were divided into two groups according to the random number table method. They were treated with different methods:
550 cases of patients were treated with 2% liranaftate ointment for external use in the observation group and the rest 550 cases of patients were treated with 1% bifonazole cream in the control group. The treatment time was two weeks for patients with tinea corporis and cruris and four weeks for those with tinea pedis respectively. Meanwhile, the one-month follow-up visit was conducted among the patients to compare the curative effects of two groups. After the medication, the curative effectiveness rate was 87.65% [482/550] in the observation group, while that was 84.91% [467/550] in the control group. After the average follow-up visits of [15.5 +/- 2.4], the curative effectiveness rate 96.55% [531/550] in the observation group, while that was 91.45% [503/550] in the control group. Two groups of patients recovered well with a low incidence of adverse reactions in the treatment, and the overall curative effect was good with the inter-group difference at P>0.05, so it was without statistical significance. The curative effect of 2% liranaftate ointment is safe and obvious in treating tinea pedis and tinea corporis and cruris, so it is valuable for clinical popularization and application
Search on Google
Index:
IMEMR
Main subject:
Ointments
/
Pyridines
/
Safety
/
Thiocarbamates
/
Tinea Pedis
/
Naphthalenes
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
Pak. J. Pharm. Sci.
Year:
2017